Notifications
Clear all
Topic starter
01/08/2026 8:54 pm
TL;DR: Continuous penetration testing can replace episodic assessments with continuous assurance across AWS-hosted applications, reducing false positives and improving remediation confidence for highly regulated life sciences workloads, according to Terra. The shift matters because continuous validation only works when authentication, exploitability, and governance are handled as an operational control, not a one-off test.
NHIMG editorial — based on content published by terra: Evinova delivers continuous product security assurance at enterprise velocity in life sciences
Questions worth separating out
Q: How should security teams run continuous pentesting without disrupting production workflows?
A: Use narrow test scopes, explicit approval paths, and evidence collection that is aligned to release cycles.
Q: Why do point-in-time assessments fail in fast-moving cloud application environments?
A: Because the attack surface changes faster than the assessment window.
Q: What do security teams get wrong about AI-generated penetration testing findings?
A: The main mistake is treating AI output as proof rather than as a lead.
Practitioner guidance
- Tie offensive testing to release events Map continuous validation triggers to deployment frequency, API changes, and integration updates so security evidence reflects the current attack surface.
- Require governed authentication for testing agents Define how any autonomous or semi-autonomous testing system authenticates, what MFA pathways it can use, and which approvals are required for production-adjacent access.
- Prioritise validated exploitability over raw findings Adjust triage workflows so remediation starts with evidence that an issue is reachable and exploitable, not merely detected.
What's in the full article
terra's full article covers the operational detail this post intentionally leaves for the source:
- Deployment context for Terra's AWS-native control plane and how it fits into production testing workflows
- Details on the MFA-based autonomous authentication capability used during deployment
- Reported outcomes on false positive reduction, remediation confidence, and continuous attack surface visibility
- How human-in-the-loop governance was structured around autonomous AI agents
👉 Read terra's analysis of continuous pentesting for regulated AWS life sciences apps →
Continuous pentesting for AWS life sciences apps: are your controls keeping up?
Explore further
01/08/2026 9:03 pm
Continuous validation is becoming a governance requirement, not just a testing preference. When application change rates outpace assessment cycles, point-in-time security work creates false confidence. The article shows why regulated teams need evidence that follows delivery velocity, not evidence that arrives after the risk has already shifted. Practitioners should treat continuous assurance as part of release governance, especially where AWS-hosted services expose customer or clinical data.
A question worth separating out:
Q: How do organisations know whether continuous pentesting is actually reducing risk?
A: Look for fewer stale findings, faster remediation of validated issues, and better alignment between test coverage and current release activity. The signal is not volume, but the proportion of findings that are exploitable and acted on quickly. That shows the control is tracking real exposure instead of generating noise.
👉 Read our full editorial: Continuous pentesting for AWS life sciences apps: what it changes
